The redundancy of HER receptor family members can vicariate EGFR inhibition as the HER2 gene is amplified in 3% of CRC patients and has been linked to a worse prognosis during anti-EGFR therapy [68]. This evidence concerns the gene ERBB2 and colorectal carcinoma.